Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Aug 2016
Randomized Controlled TrialOPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.
Peripheral leukocytes in patients with atopic dermatitis (AD) have elevated phosphodiesterase-4 activity, which is associated with production of proinflammatory mediators. OPA-15406 is a phosphodiesterase-4 inhibitor with high selectivity for phosphodiesterase-4-B. ⋯ OPA-15406 ointment may provide an effective therapeutic modality for patients with mild to moderate AD.
-
Early and complete removal of ticks using the right technique is important to reduce tick-transmitted diseases. Several chemical and mechanical detachment techniques have been described previously. ⋯ Tick detachment using tweezers, performed in an appropriate manner, is the easiest and most effective technique.